Date Title Description PDF
03 Nov 2021 On buy-back programmes The Company reports the commencement, effective as of today, 3 November 2021, of a share buyback program. Download
16 Jul 2021 On Corporate Governance ROVI announces the appointment of Juan López-Belmonte Encina as Chairman of the Company   Download
22 Jun 2021 On significant placements in financial instruments Bestinver announces the beginning of an accelerated book build process of up to a 3% of the share capital of Laboratorios Rovi, S.A. Download
22 Jun 2021 On significant placements in financial instruments Hereby inform of the completion of the private placement package. The amount of the Placement amounted to a total of 87.88 million euros, being the unit selling price of 52.25 euros per share. Download
29 Apr 2021 On business and financial situation The Company informs about the increase of its fill-finish capacity for the manufacture of Moderna’s COVID-19 vaccine outside the United States.     Download

Pages

Date Title Description PDF
21 Oct 2021 On business and financial situation The Company informs of the delay in the decision on Risperidone ISM® by the U.S. Food and Drug Administration (“FDA”). Download
21 Oct 2021 Liquidity and counterparty agreements Download
07 Oct 2021 Liquidity and counterparty agreements Download
04 Oct 2021 Liquidity and counterparty agreements Download
01 Sep 2021 On business and financial situation ROVI informs about the joint statement from Moderna and Takeda on the investigation of suspended lots of the vaccine Download

Pages

Date Title Description PDF
21 Feb 2012 Información sobre resultados (2) Download
21 Feb 2012 Información sobre resultados Download
21 Feb 2012 Informe Anual de Gobierno Corporativo Download
15 Feb 2012 Cambios en política de inversión, áreas de negocio y líneas de productos Download
22 Dec 2011 Composición del Consejo de Administración Download

Pages